First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. Science ShareTwitterFacebookXingLinkedin dysgeusiaP2X3 receptor antagonistspharmacokineticstaste perception You May Also Like Science 30. Januar 2023 Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects. Science 30. Januar 2023 Midazolam microdosing applied in early clinical development for drug-drug interaction assessment. Science 30. Januar 2023 The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.
